Primær biliær kolangitt
Sist revidert:
Sist revidert av:Terje Johannessen
Definisjon:
En autoimmun, kronisk, kolestatisk sykdom i de intrahepatiske galleganger med inflammasjon, fibrose og til slutt leversvikt. Sykdommen ble tidligere kalt primær biliær cirrhose
Forekomst:
Sjelden. Prevalens 150-400 per million
Symptomer:
Tidlige tegn er slapphet, plagsom kløe og uforklarlig hyperlipidemi
Funn:
Hepatosplenomegali, hyperpigmentering, xantomatøse lesjoner kan forekomme i hud, sener eller rundt øyebryn. Ikterus eventuelt, men er et sent innsettende tegn
Diagnostikk:
Biokjemiske prøver viser kolestatisk mønster. Anti-mitokondrie-antistoffer har høy sensitivitet og spesifisitet
Behandling:
Primært symptomatisk. Ursodeoksykolsyre brukes mye, men har usikker effekt
- Jones DEJ, Mackay IR, Snyder N. Primary biliary cirrhosis. BMJ Best Practice, last updated Jan 10, 2017.
- Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003; 362: 53-61. PubMed
- Jørgensen KK. Primær biliær cholangitt – sjelden sykdom med nytt navn. Gastroenterologen. Publisert 20.10.2017. Siden besøkt 28.10.2019 gastroenterologen.no
- Prince MI, Chetwynd A, Diggle P, Jarner M, Metcalf JV, James OF. The geographical distribution of primary biliary cirrhosis in a well-defined cohort. Hepatology 2001; 34: 1083-88. PubMed
- Lazaridis KN, Talwalkar JA. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol 2007; 41: 494-500. PubMed
- Kim WR, Lindor KD, Locke GR III, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119: 1631-6. Gastroenterology
- Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-73. New England Journal of Medicine
- Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2008; 357: 1524-9. PubMed
- He XS, Ansari AA, Ridgway WM, Coppel RL, Gershwin ME. New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis. Cell Immunol 2006; 239: 1-13. PubMed
- Selmi C, Balkwill DL, Invernizzi P, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003; 38: 1250-7. PubMed
- Ueno Y, Moritoki Y, Shimosegawa T, Gershwin ME. Primary biliary cirrhosis: what we know and what we want to know about human PBC and spontaneous PBC mouse models. J Gastroenterol 2007; 42: 189-95. PubMed
- Jones DE. Pathogenesis of primary biliary cirrhosis. J Hepatol 2003; 39: 639-48. PubMed
- Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OF. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology 2000; 31: 1055-60. PubMed
- Zein CO, Angulo P, Lindor KD. When is a liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 2003; 1: 89-96. PubMed
- Rudic JS, Poropat G, Krstic MN et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews, Dec 2012, CD000551.pub3. Cochrane (DOI)
- Ozaslan E, Efe C, Heurgué-Berlot A3, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol 2014 doi:10.1016/j.cgh.2013.09.021 DOI
- Poupon R. Overview of the treatment of primary biliary cholangitis. UpToDate, last updated Mar 04, 2019. UpToDate
- Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders." J Hepatol 2001; 35: 134-46.
- Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36: 525-31. PubMed
- Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 1529-38. PubMed
- Siegel JL, Jorgensen R, Angulo P, Lindor KD. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol 2003; 37: 183-5. PubMed
- Nevens F, Andreone P, Mazzella G, et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. 2016; 375: 631-43. PMID: 27532829 PubMed
- Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50: 436-39. Gut
- Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005; 42: 762-71. PubMed
- Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33: 22-27. PubMed
- ter Borg PCJ, Schalm SW, Hansen B, van Buuren HR. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis: results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 2044-50. PubMed
- Corpechot C, Carrat F, Bahr A, Chrétein Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297-303. Gastroenterology
- Terje Johannessen, professor i allmennmedisin, Trondheim (tilpasning til NEL)
Tidligere fagmedarbeidere
- Eiliv Brenna, overlege, Medisinsk avdeling, Regionsykehuset i Trondheim
- Svein Ødegaard, overlege og professor, Haukeland sykehus og Nasjonalt senter for gastroenterologisk ultrasonografi, Bergen